The present observations raise the possibility of exploiting CLDN3 and CLDN4 as potential biomarkers for ovarian cancer progression and highlight maintenance of E-cadherin levels as a target for therapeutic intervention. Here, CLDN3 is linked to ovarian carcinoma.